NasdaqCM:SLNOBiotechs
A Look At Soleno Therapeutics (SLNO) Valuation After Profitable Q4 2025 And VYKAT XR Adoption
Soleno Therapeutics (SLNO) is back in focus after releasing preliminary Q4 and full year 2025 figures that highlight VYKAT XR adoption in Prader Willi syndrome, initial profitability, positive cash flow, and updated revenue guidance.
See our latest analysis for Soleno Therapeutics.
Despite the recent guidance and clinical publication, the stock has been under pressure, with a 30 day share price return of 20.12% and a 90 day share price return of 38.61%. Even so, the 3 year total shareholder...